These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8786971)

  • 1. Acceleration of nitric oxide (NO) release from FK409, a spontaneous NO releaser, in the presence of sulfhydryl-bearing compounds.
    Fukuyama S; Hirasawa Y; Cox D; Koda S; Kita Y
    Pharm Res; 1995 Dec; 12(12):1948-52. PubMed ID: 8786971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet activities of FK409, a new spontaneous NO releaser.
    Kita Y; Hirasawa Y; Yoshida K; Maeda K
    Br J Pharmacol; 1994 Oct; 113(2):385-8. PubMed ID: 7834188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitric oxide (NO)-releasing pathway of FK409 in the presence of sulfhydryl-bearing compounds.
    Fukuyama S; Azuma T; Hirasawa Y; Morokoshi N; Akama T; Koda S; Kita Y
    Pharm Res; 1996 Aug; 13(8):1238-42. PubMed ID: 8865319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409.
    Kita Y; Hirasawa Y; Maeda K; Nishio M; Yoshida K
    Eur J Pharmacol; 1994 May; 257(1-2):123-30. PubMed ID: 8082692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships of spontaneous nitric oxide releasers, FK409 and its derivatives.
    Fukuyama S; Hirasawa Y; Kato Y; Nishio M; Ohno M; Nishino S; Maeda K; Kato M; Kita Y
    J Pharmacol Exp Ther; 1997 Jul; 282(1):236-42. PubMed ID: 9223559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of antiplatelet effects of two nitric oxide-donating agents, FR146801 and FK409.
    Hirasawa Y; Kato Y; Fukuyama S; Ohno M; Nishino S; Kato M; Kita Y
    Thromb Haemost; 1998 Mar; 79(3):620-4. PubMed ID: 9531052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antianginal effects of FK409, a new spontaneous NO releaser.
    Kita Y; Ozaki R; Sakai S; Sugimoto T; Hirasawa Y; Ohtsuka M; Senoh H; Yoshida K; Maeda K
    Br J Pharmacol; 1994 Dec; 113(4):1137-40. PubMed ID: 7889266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of antiplatelet effects of FK409, a spontaneous nitric oxide releaser, with those of TRK-100, a prostacyclin analogue.
    Hirasawa Y; Nishio M; Maeda K; Yoshida K; Kita Y
    Eur J Pharmacol; 1995 Jan; 272(1):39-43. PubMed ID: 7713147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Close correlation between nitric oxide (NO) formation from NO releasers and the biological activities of these agents in rats.
    Kita Y; Fukuyama S; Hirasawa Y
    Jpn J Pharmacol; 1995 Sep; 69(1):69-74. PubMed ID: 8847834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FR144420, a novel, slow, nitric oxide-releasing agent.
    Kita Y; Ohkubo K; Hirasawa Y; Katayama Y; Ohno M; Nishino S; Kato M; Yoshida K
    Eur J Pharmacol; 1995 Mar; 275(2):125-30. PubMed ID: 7796846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new nitric oxide (NO) releaser: spontaneous NO release from FK409.
    Fukuyama S; Kita Y; Hirasawa Y; Azuma T; Sato A; Morokoshi N; Koda S; Yasuda T; Oka S; Sakurai H
    Free Radic Res; 1995 Nov; 23(5):443-52. PubMed ID: 7581827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance to the vascular effect of a novel nitric oxide-donating vasodilator, FK409.
    Isono T; Sato N; Yamamoto T; Sawada T; Yamazaki S; Miura S; Furuichi A; Ozaki R; Koibuchi Y; Ohtsuka M
    Eur J Pharmacol; 1994 Aug; 260(2-3):163-8. PubMed ID: 7988640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty.
    Seki J; Nishio M; Kato Y; Motoyama Y; Yoshida K
    Atherosclerosis; 1995 Sep; 117(1):97-106. PubMed ID: 8546759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral biological activities of spontaneous nitric oxide releasers are accounted for by their nitric oxide-releasing rates and oral absorption manners.
    Kita Y; Hirasawa Y; Fukuyama S; Ohkubo K; Kato Y; Takamatsu H; Ohno M; Nishino S; Kato M; Seki J
    J Pharmacol Exp Ther; 1996 Feb; 276(2):421-5. PubMed ID: 8632305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Close correlation of the cardioprotective effect of FK409, a spontaneous NO releaser, with an increase in plasma cyclic GMP level.
    Kita Y; Sugimoto T; Hirasawa Y; Yoshida K; Maeda K
    Br J Pharmacol; 1994 Sep; 113(1):5-6. PubMed ID: 7812632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of hemodynamic effects of nitric oxide (NO) donors with different NO-releasing properties in rats.
    Kita Y; Hirasawa Y; Kato Y; Ohkubo K; Ohno M; Nishino S; Kato M; Fukuyama S
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):223-8. PubMed ID: 9269950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction of FK409, a novel nitric oxide releaser, and peripherally administered morphine during experimental inflammation.
    Nozaki-Taguchi N; Yamamoto T
    Anesth Analg; 1998 Feb; 86(2):367-73. PubMed ID: 9459250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects of FK409, a novel nitric oxide donor, against postischemic myocardial dysfunction in guinea-pig hearts.
    Cao Y; Hotta Y; Shioi K; Nagata Y; Kawai N; Ishikawa N
    J Cardiovasc Pharmacol; 2001 Oct; 38(4):593-605. PubMed ID: 11588530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasorelaxant mechanism of the new vasodilator, FK409.
    Isono T; Koibuchi Y; Sato N; Furuichi A; Nishii M; Yamamoto T; Mori J; Kohsaka M; Ohtsuka M
    Eur J Pharmacol; 1993 Aug; 246(3):205-12. PubMed ID: 7901040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal hemodynamic and excretory responses in anesthetized rats to FK409, a novel nitric oxide donor.
    Urabe K; Matsumura Y; Nishiura M; Maeda K; Morimoto S
    Eur J Pharmacol; 1997 Feb; 321(2):195-200. PubMed ID: 9063688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.